Atomwise is a preclinical pharma company revolutionizing drug discovery with AI. They have invented the use of deep learning for structure-based drug discovery and are developing a pipeline of small-molecule drug candidates. Their AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. Atomwise is tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies.

Atomwise

Iambic Therapeutics develops AI-driven platforms for drug discovery, focusing on optimizing medicines for specific disease profiles and addressing unmet patient needs. The company self-describes its approach as innovative and efficient.

Iambic Therapeutics

AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

Biomatter develops proteins and enzymes with Intelligent Architecture™ for health and sustainable manufacturing. The company provides solutions from initial concept to protein production.

Biomatter

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. 

We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. 

We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

Bill & Melinda Gates Foundation

Sanabil

AME Cloud Ventures

Y Combinator

Baidu Ventures

DCVC

Dolby Family Ventures

Tencent

Colorcon

Touchdown Ventures

Atomwise is revolutionizing how drugs are discovered using #AI. Our deep learning technology for structure-based drug discovery enables our pipeline of small-molecule drug candidates. 

Learn more about Atomwise and how we’re changing traditional #drugdiscovery ⬇️

We're excited to announce the nomination of our very first AI-driven development candidate, focused on TYK2 inhibition. This marks a significant milestone in our journey to revolutionize drug discovery and development through artificial intelligence.

Joining us on this incredible venture is Dr. Neely Mozaffarian, MD, PhD, who has been appointed as our new Chief Medical Officer. With her expertise and leadership, we're poised to advance groundbreaking solutions that could transform the lives of millions.

At Atomwise, we're committed to using AI to accelerate drug discovery and improve patient outcomes. This appointment and our strategy are a testament to our dedication to creating #FirstInClass and #BestInClass medicines for patients. 

Stay tuned for more updates as we continue to push the boundaries of what's possible in medicine and science! 

#AI #DrugDiscovery #HealthcareInnovation #TYK2Inhibition #Atomwise

https://lnkd.in/ecSizR_6

Tomorrow is the Day! Greg Friedland, Sr. Principal Software Engineer at @Atomwise will be presenting at the upcoming ACS Fall Symposium "Taking a Deep Dive into the Chemical Space” on August 16th. His presentation is titled "Complementary Methods for Exploring Ultra-large Combinatorial Synthesis Libraries in Fragment-space," work of which was done in collaboration with his fantastic co-authors Saulo de Oliveira, Aryan Pedawi, Adrian Morrison, and Henry van den Bedem, + many more esteemed colleagues at Atomwise. Make sure you catch Greg and the other speakers in this symposium as they "Deep Dive into the Chemical Space!"

#AI  #drugdiscovery

https://hubs.la/Q01_3Kk00



Metric
Company Name	Atomwise	Iambic Therapeutics	AMPLY Discovery	Biomatter
Symbol
MSH ID	COM:ATOMWISE	AI:IAMBIC	COM:AMPLYDISCOVERY	COM:BIOMATTER
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Technology
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Biotechnology
Country	US	US	GB	LT
Stage
Employee Count	73	59	7
Website	atomwise.com	iambic.ai	amplydiscovery.com	biomatter.com
LinkedIn	atomwise			biomatter
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	54.13	9.97
28-Day Growth Score	12.90	6.64
90-Day Growth Score	54.79	6.30
365-Day Growth Score	81.66	34.06

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ATOMWISE

Atomwise

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue